McClung, M. R, Miller, P. D, Brown, J. P, Zanchetta, J., Bolognese, M. A, Benhamou, C. L, Balske, A., Burgio, D. E, Sarley, J., McCullough, L. K & Recker, RR. (2012). Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet. Osteoporosis International,23(1), 267-276. United Kingdom: Springer Verlag. Retrieved from https://doi.org/10.1007/s00198-011-1791-y
Dosing regimens of oral bisphosphonates are inconvenient and contribute to poor compliance. The bone mineral density response to a once weekly delayed-release formulation of risedronate given before or following breakfast was non-inferior to traditional immediate-release risedronate given daily before breakfast. Delayed-release risedronate is a convenient regimen for oral bisphosphonate therapy.
Institute for Health and Ageing
Access may be restricted.